Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xianling Liu

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
American Journal of Physiology. Endocrinology and Metabolism|February 26, 2009
Downregulation of Grb2 contributes to the insulin-sensitizing effect of calorie restrictionXianling Liu, Meilian Liu, Jingjing Zhang, et al.
Therapeutics and Clinical Risk Management|December 10, 2020
Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching AnalysisJin Li, Yajun Li, Ruolan Zeng, et al.
Clinical Pharmacology and Therapeutics|December 1, 2023
Circulating Tumor DNA Profiling Approach Based on In Silico Background Elimination Guides Chemotherapy in Nasopharyngeal CarcinomaMing Li, Sisi Xie, Tao Hou, et al.
Journal of Thrombosis and Thrombolysis|June 12, 2020
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysisBilian Yu, Xin Li, Jin Chen, et al.
Frontiers in Oncology|October 10, 2022
A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signalingYang Zhang, Zhihua Wang, Guoyu Hu, et al.
Frontiers in Oncology|February 13, 2023
Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancerXingsheng Hu, Chunhong Hu, Xianling Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 3, 2024
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical TrialZhiwei Chen, Lin Wu, Qiming Wang, et al.
Cancer Medicine|November 24, 2023
Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology GroupHuawei Weng, Prem Raj Shrestha, Huangming Hong, et al.
Frontiers in Immunology|June 23, 2023
Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancerChaoyuan Liu, Liang Zeng, Chao Deng, et al.
Translational Lung Cancer Research|March 4, 2022
A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resectionChunhong Hu, Long Shu, Chen Chen, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
American Journal of Physiology. Endocrinology and Metabolism|February 26, 2009
Downregulation of Grb2 contributes to the insulin-sensitizing effect of calorie restrictionXianling Liu, Meilian Liu, Jingjing Zhang, et al.
Therapeutics and Clinical Risk Management|December 10, 2020
Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching AnalysisJin Li, Yajun Li, Ruolan Zeng, et al.
Clinical Pharmacology and Therapeutics|December 1, 2023
Circulating Tumor DNA Profiling Approach Based on In Silico Background Elimination Guides Chemotherapy in Nasopharyngeal CarcinomaMing Li, Sisi Xie, Tao Hou, et al.
Journal of Thrombosis and Thrombolysis|June 12, 2020
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysisBilian Yu, Xin Li, Jin Chen, et al.
Frontiers in Oncology|October 10, 2022
A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signalingYang Zhang, Zhihua Wang, Guoyu Hu, et al.
Frontiers in Oncology|February 13, 2023
Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancerXingsheng Hu, Chunhong Hu, Xianling Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 3, 2024
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical TrialZhiwei Chen, Lin Wu, Qiming Wang, et al.
Cancer Medicine|November 24, 2023
Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology GroupHuawei Weng, Prem Raj Shrestha, Huangming Hong, et al.
Frontiers in Immunology|June 23, 2023
Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancerChaoyuan Liu, Liang Zeng, Chao Deng, et al.
Translational Lung Cancer Research|March 4, 2022
A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resectionChunhong Hu, Long Shu, Chen Chen, et al.
Pageof 12